NICE approves adalimumab for psoriasis

NICE has published guidance on the use of adalimumab (Humira), an anti-TNF agent for the treatment of psoriasis.

It recommends adalimumab as a treatment option for adults with plaque psoriasis for whom anti-TNF treatment is being considered and when both of the following criteria are fulfilled:

  • The disease is severe (defined as a Psoriasis Area Sensitivity Index [PASI] and a Dermatology Life Quality Index [DLQI] of more than 10).
  • The disease has not responded to previous therapies including ciclosporin, methotrexate and PUVA, or the patient is intolerant or has a contraindication to these treatments.
  • Adalimumab should be discontinued in patients whose psoriasis has not responded adequately at 16 weeks.

Read the full NICE guidance

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Correct vitamin D deficiency to reduce COPD exacerbations, say researchers

Vitamin D supplements could nearly halve the rate of...

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Launch of new SGLT2 inhibitor increases choice in diabetes prescribing

Ertugliflozin (Steglatro) is a sodium glucose co-transporter...